Breaking News
Investing Pro 0
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started

AbbVie looks to new drugs to boost sales following Humira competition - WSJ

Stock Markets Feb 06, 2023 17:36
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters
 
ABBV
+0.92%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
+0.10%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

AbbVie (NYSE:ABBV) is looking towards its new drugs to replace Humira now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall Street Journal said Monday.

The WSJ said that the drugmaker's Chief Executive, Richard Gonzalez, revealed the company is turning to a pair of next-generation successors to reload the billions of dollars in sales that will be lost.

In addition, AbbVie is betting on four drug approvals by the end of next year while also lifting a self-imposed $2 billion limit on the deal sizes it would conduct to add more products.

Gonzalez was quoted as saying in an interview that they "knew this day would come" while it built a strategy and "executed that strategy" to ensure the company could "absorb this impact, and then immediately return to growth."

It comes after Amgen (NASDAQ:AMGN) began selling its near-identical version of Humira in the U.S. last week at a list price of up to 55% below AbbVie's.

The biosimilar is a big blow for AbbVie as Humira has been among the top-selling medicines in the U.S., accumulating over $135B in U.S. sales since its launch two decades ago.

As a result, AbbVie sales are expected to decline significantly next year, but the company is aiming to remedy the lost sales with two newer immune drugs, Skyrizi and Rinvoq, according to the WSJ.

The drugs are said to be more effective than Humira and treat the same immune conditions as Humira. In addition, the company sees them passing Humira's peak sales in four years.

Furthermore, AbbVie has an experimental Parkinson's treatment that is currently under regulatory review, as well as therapies in late-stage testing for myelofibrosis and lung cancer that could win approval next year.

AbbVie looks to new drugs to boost sales following Humira competition - WSJ
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email